This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): EC0225
Description: EC0225 uses Endocyte’s proprietary linker technology to attach two potent chemotherapeutic agents (a vinca alkaloid and mitomycin C) onto a single folate molecule. The vinca alkaloids are also called antimitotic or antimicrotubule agents, or mitotic inhibitors.
Deal Structure: In April 2012, Merck and Endocyte entered into an agreement to develop and commercialize vintafolide (EC145). Enocyte has also stated that the agreement includes EC0225 and EC0489.
Under the agreement, Merck will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a $120 million upfront payment and is eligible for milestone payments of up to $880 million based on the successful achievement of development, regulatory and commercialization goals for vintafolide for a total of six cancer indications. In addition, if vintafolide receives regulatory approval, Endocyte will receive an equal share of the profit in the United States (U.S.) as well as a double digit percentage royalty on sales of the product in the rest of the world.
Endocyte has retained the right to co-promote vintafolide with Merck in the U.S. and Merck has the exclusive right to promote vintafolide in the rest of world. Endocyte will be responsible for the majority of funding and...See full deal structure in Biomedtracker
Partners: Endocyte, Inc.
Pink Sheet Chart: FDA Recalls -- July 8, 2009
Pink Sheet Syntex EC-Naprosyrn
Additional information available to subscribers only: